Edinburgh Napier University

  Background: Introduction of the new HCV protease inhibitors has been shownto improve outcomes for mono-infected patients. Recent data showssignificant decline in HCV RNA at 24 weeks in genotype 1 co-infectedpatients on HAART who received either Telaprevir or Boceprevir in combinationwith Peginterferon and Ribavirin versus those who received current standardof care. We reviewed the proportion of our HCV/HIV co-infected patients whowould be suitable for treatment with the new HCV protease inhibitors.Methods: The case records of all HCV co-infected patients on the unitdatabase were reviewed to assess if they would be candidates for standard ofcare plus a protease inhibitor. The criteria used were: an undetectable HIV viralload, CD4>200 cells/mL3, stable on any HAART regime or able to switch to aregime that has suitable PK data with new protease inhibitors, no significantpsychiatric illness and no previous significant side-effects with Interferon orRibavirin.Results: A total of 74 (58 naı¨ve, 16 experienced) HCV co-infected patientswere assessed. Only 1 patient could not switch HAART based on drug-druginteractions. 25/58 patients in the naı¨ve group could not be treated largely dueto pre-existing psychiatric problems. 6/16 of the experienced group could notbe treated mostly due to previous Interferon and Ribavirin side effects.Exclusion Criteria Naı¨veN=58 ExperiencedN=16Psychiatric illness 12 1Detectable HIV Viral Load 9 1CD4